Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies.

Journal: Antiviral therapy
Published Date: Nov 26, 2021

Abstract

BACKGROUND: To evaluate the long-term safety and efficacy of rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), in combination with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) in human immunodeficiency virus (HIV)-infected patients.

Authors

  • Jean Michel Molina
    University of Paris, Department of Infectious Diseases, St-Louis and Lariboisière hospitals, APHP, Paris, France.
  • Luminita Ene
    Spitalul de Boli Infectioase si Tropicale "Dr. Victor Babes" Bucuresti, Sos, Bucuresti, Romania.
  • Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina.
  • Gerd Fätkenheuer
    Department of Internal Medicine, University of Cologne, KerpenerStraße, Cologne, Germany.
  • Eric Van Wijngaerden
    Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium.
  • Johan Lombaard
    379336Josha Research, Bloemfontein, South Africa.
  • Natalia Zakharova
    Centre for Prophylaxis and Control of AIDS and Infectious Diseases, St. Petersburg, Russia.
  • Veerle Van Eygen
    Janssen Research & Development, Turnhoutseweg, Beerse, Belgium.
  • Simon Vanveggel
    Janssen Research & Development, Turnhoutseweg, Beerse, Belgium.
  • Rodica Van Solingen-Ristea
    Janssen Research & Development, Turnhoutseweg, Beerse, Belgium.

Keywords

External Resources

Popular Topics
Recent Journals